Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2 (TBL)

NCT03278483 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

396

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus
Tuberculin (Skin Test) Positive

Interventions

DRUG: Isoniazid 300 mg Oral Tablet
DRUG: Rifampin 600 mg Oral Tablet

Sponsor

Instituto Nacional de Salud Publica, Mexico

Collaborators

[object Object]
[object Object]